Category: 27372-38-9

Related Products of 27372-38-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.27372-38-9, Name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, molecular formula is C5H6N2O3. In a Patent，once mentioned of 27372-38-9

The present invention provides a semicarbazone compound preparation method and application in biomedicine. The compound is a compound of formula (I) or an enantiomer, a diastereomer, a raceme, a pharmaceutically acceptable salt, a crystalline hydrate or a solvate thereof. The compound has the formula shown in the description, wherein X is sulfur or oxygen; R1 and R2 are separately and independently hydrogen and alkyl containing 1-3 carbon atoms or N=CHR 5, wherein R5 is optionally substituted aryl or optionally substituted alkyl; R3 and R4 are separately and independently hydrogen or alkyl containing 1-3 carbon atoms or substituents selected from formulas III, III, IV, and V shown in the description, wherein X1 is sulfur or oxygen. Y, Y1 and Y2 are separately and independently at least one of hydrogen, alkyl containing 1-3 carbon atoms, halogen, hydroxy, methoxy, amino, sulfonic acid group, nitro, carboxyl, thiol, methylamino, ethylamino, dimethylamino or diethylamino; and Z1 is hydrogen, alkyl containing 1-3 carbon atoms, halogen, hydroxy, amino, methylamino, ethylamino, dimethylamino or diethylamino. The semicarbazone compound is applicable to related diseases caused by copper metabolic dysfunction.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 27372-38-9, and how the biochemistry of the body works.Related Products of 27372-38-9

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N1012 – PubChem

 

Electric Literature of 27372-38-9, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 27372-38-9, Name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, molecular formula is C5H6N2O3. In a Article，once mentioned of 27372-38-9

Copper-catalyzed aerobic dehydrogenation of C-C to C=C bonds in the synthesis of pyridazinones

A simple and efficient procedure for the synthesis of pyridazin-3(2H)-ones through copper-catalyzed dehydrogenation of a single C-C bond of 4,5-dihydropyridazin-3(2H)-ones to a C=C bond with oxygen as the terminal oxidant is described. Functional groups including hydroxy, carboxylic, bromo, chloro, cyano, nitro and alkoxy were all tolerated under the reaction conditions. Moreover, this methodology was applied to the preparation of a series of structurally similar N-substituted 6-phenylpyridazinone compounds containing fluorine. The dehydrogenation reactions exhibit good yields and selectivity. Copper-catalyzed dehydrogenation of a C-C bond of 4,5-dihydropyridazinones to a C=C bond with oxygen as the terminal oxidant is described. Various functional groups were tolerated under the reaction conditions. The method was also applied to the preparation of a series of N-substituted 6-phenylpyridazinones containing fluoride. The dehydrogenation reactions exhibit good yields and selectivity.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Electric Literature of 27372-38-9. In my other articles, you can also check out more blogs about 27372-38-9

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N1018 – PubChem

 

Chemistry is traditionally divided into organic and inorganic chemistry. Application In Synthesis of 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 27372-38-9

Studies on anti-platelet agents. V. Synthesis and structure-activity relationship of 3-substituted 5,6-bis(4-methoxyphenyl)-1,2,4-triazines

The syntheses and structure-activity relationships of a series of 3-substituted 5,6-bis(4-methoxyphenyl)-1,2,4-triazines as anti-platelet agents based on cyclooxygenase (CO) inhibition are described. Of these compounds, 1-[5,6-bis(4-methoxyphenyl)-1,2,4-triazin-3-yl]carbonyl-4-methylpipera zine (10) exhibited potent CO inhibition in vitro (IC50 = 2.8 x 10-7 M) with vasodilatory activity (ED50 = 4.5 x 10-5 M). Compound 10 also showed potent ex vivo activities, completely preventing platelet aggregation induced by arachidonic acid and collagen at 6 h after oral administration of 3.2 and 1.0 mg/kg. The ex vivo potency of 10 is more than three times that of aspirin. Moreover, 10 demonstrated no gastrointestinal side effect in rats even at 100 mg/kg in spite of its potent CO inhibition activity, while aspirin, the most widely-used anti-platelet drug, showed gastrointestinal side effects in a dose-dependent manner (32, 100, and 320 mg/kg) in our study. These results suggested that 10 is a very attractive candidate for development as an anti-platelet drug since an aspirin-like anti-platelet agent, based on CO inhibition and being free from gastrointestinal side effects, is a major goal of thromboembolic research.

If you are interested in 27372-38-9, you can contact me at any time and look forward to more communication. Application In Synthesis of 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1021 – PubChem

 

Related Products of 27372-38-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.27372-38-9, Name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, molecular formula is C5H6N2O3. In a Patent£¬once mentioned of 27372-38-9

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKepsilon inhibitors.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 27372-38-9, and how the biochemistry of the body works.Related Products of 27372-38-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1013 – PubChem

 

Related Products of 27372-38-9, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.27372-38-9, Name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, molecular formula is C5H6N2O3. In a Patent£¬once mentioned of 27372-38-9

Endothelin receptor antagonists

This invention relates to pyridizinone derivatives of formula I STR1 wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 27372-38-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1009 – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 27372-38-9, name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, introducing its new discovery. COA of Formula: C5H6N2O3

Solid-state and solvent-free synthesis of azines, pyrazoles, and pyridazinones using solid hydrazine

Azines, pyrazoles, and pyridazinones were isolated as the sole products in high yields (>97%) by grinding solid hydrazine (H3N +NHCO2-) with di-carbonyl compounds or by their reaction in the absence of solvent. Neither catalysts nor additives were needed to promote the reactions. The solid-state and solvent-free reactions proceeded under ambient conditions and did not produce any wastes other than water and carbon dioxide. They are operationally easy, environmentally safe, and readily scalable, allowing for highly selective synthesis of compounds containing the hydrazine motif. Copyright

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 27372-38-9, and how the biochemistry of the body works.COA of Formula: C5H6N2O3

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1017 – PubChem

 

27372-38-9, Name is 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, belongs to pyridazine compound, is a common compound. COA of Formula: C5H6N2O3In an article, once mentioned the new application about 27372-38-9.

Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles

The syntheses, biological evaluations, and structure-activity relationships of a series of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles as potent antiplatelet agents with vasodilatory activity are described. 2-Guanidino-4,5-bis(4-methoxyphenyl)thiazole (3), designed from two parent compounds (itazigrel and timegadine), showed inhibitory activity of malondialdehyde (MDA, IC50 = 31 muM) production which is formed from the cyclooxygenase (CO)-catalyzed oxygenation of arachidonic acid in the synthesis of prostanoids in platelets, with vasodilatory activity (ED50 = 2.0 muM). Further structure-activity relationship studies on 3 culminated in the preparation of 4,5-bis(4-methoxyphenyl)-2-<(1-methylpiperazin-4-yl)carbonyl>thiazole (10a, FR122047) which exhibited potent inhibitory activity on MDA synthesis in vitro (IC50 = 0.088 muM) and platelet aggregation in guinea pigs ex vivo (100percent inhibition even 6 h after 1.0 mg/kg administration) with vasodilatory activity in vitro (ED50 = 6.2 muM). Moreover, 10a demonstrated no ulcerogenesis effect in rats even at 100 mg/kg dosage (safety margin in rats is more than 70 while that of aspirin is only 1.2) in spite of its potent CO inhibition (IC50 = 0.43 muM), while the use of aspirin, a CO inhibitor and the most popular thromboembolic drug, is restricted by the side effect. Pharmacokinetic studies on 10a have revealed that 10a is detectable in platelet-rich plasma but not in platelet-poor plasma 1 day after oral administration, which indicates that 10a tends to be localized in platelets. This property could be responsible for its low toxicity and reduction of side effects in clinical studies.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 27372-38-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1020 – PubChem

 

27372-38-9, 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6-oxo-1,6-dihydropyridazine-3-carboxylic acid To a solution of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (2.50 g, 17.59 mmol) in toluene (44 mL) was added Cu(OAc)2 (450 mg, 2.48 mmol), sodium carbonate (7.01 g, 66.14 mmol) and pyridine (4.4 mL) at room temperature. The resulting solution was stirred for 16 h at 100 C. After the reaction was done, the insoluble solids in the reaction mixture were filtered out and the filtrate was concentrated under reduced pressure to yield 6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a off-white solid (1.80 g, 73%). MS: m/z=177.0 [M+H]+., 27372-38-9

27372-38-9 6-Oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid 99621, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; Merck Patent GmbH; SHERER, Brian A.; KARRA, Srinivasa; XIAO, Yufang; (407 pag.)US2016/376283; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem